Renal co-morbidity in patients with rheumatic diseases

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Anders, Hans Joachim ^a   Vielhauer, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; COLCHICINE; CREATININE; CYCLOSPORIN; DIPYRONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FEBUXOSTAT; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANCA ASSOCIATED VASCULITIS; ARTHROPATHY; AUTOIMMUNE DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; GIANT CELL ARTERITIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNE COMPLEX DISEASE; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; POLYARTERITIS NODOSA; PROTEINURIA; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY;

AUTOIMMUNE DISEASES; COMORBIDITY; HUMANS; KIDNEY DISEASES; RHEUMATIC DISEASES;

EID: 84855715161     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3256     Document Type: Review

References (64)

1. Hill AJ, Thomson RJ, Hunter JA, Traynor JP. The prevalence of chronic kidney disease in rheumatology outpatients. Scott Med J 2009, 54:9-12. 10.1258/rsmsmj.54.2.9, 19530494.
2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266. National Kidney Foundation.
3. Anders HJ, Rihl M, Loch O, Schattenkirchner M. Prediction of creatinine clearance from serum creatinine in patients with rheumatoid arthritis: comparison of six formulae and one nomogram. Clin Rheumatol 2000, 19:26-29. 10.1007/s100670050006, 10752495.
4. Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M. Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol 2002, 8:130-133. 10.1097/00124743-200206000-00002, 17041340.
5. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations. Lupus 2007, 16:887-895. 10.1177/0961203307084167, 17971362.
6. Siedner MJ, Christopher-Stine L, Astor BC, Gelber AC, Fine DM. Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists. J Rheumatol 2007, 34:973-977.
7. Siedner MJ, Gelber AC, Rovin BH, McKinley AM, Christopher-Stine L, Astor B, Petri M, Fine DM. Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. J Rheumatol 2008, 35:84-90.
8. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983, 309:1543-1546. 10.1056/NEJM198312223092503, 6656849.
9. Salesi M, Karimifar M, Farajzadegan Z, Esalatmanesh K, Khosravi S, Fallahi P, Akbarian M. The protein-creatinine ratio in spot morning urine samples and 24-h urinary protein excretion in patients with systemic lupus erythematosus. Rheumatol Int 2009, 29:503-507. 10.1007/s00296-008-0742-1, 18953541.
10. Leung YY, Szeto CC, Tam LS, Lam CW, Li EK, Wong KC, Yu SW, Kun EW. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology (Oxford) 2007, 46:649-652.
11. Koseki Y, Terai C, Moriguchi M, Uesato M, Kamatani N. A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 2001, 60:327-331. 10.1136/ard.60.4.327, 1753620, 11247860.
12. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008, 47:350-354.
13. Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995, 38:242-247. 10.1002/art.1780380213, 7848315.
14. Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, Kuroda T, Sato T, Maruyama Y, Arakawa M. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998, 50:154-160.
15. Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Kautiainen H, Hakala M. Steep decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol 2009, 38:403.
16. Scott DG, Bacon PA, Elliott PJ, Tribe CR, Wallington TB. Systemic vasculitis in a district general hospital 1972-1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med 1982, 51:292-311.
17. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984, 76:377-384. 10.1016/0002-9343(84)90654-5, 6142648.
18. Sihvonen S, Korpela M, Mustonen J, Laippala P, Pasternack A. Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 2004, 96:c107-c114. 10.1159/000077372, 15122064.
19. Vilar MJ, Cury SE, Ferraz MB, Sesso R, Atra E. Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 1997, 26:19-23. 10.3109/03009749709065659, 9057797.
20. Alenius GM, Stegmayr BG, Dahlqvist SR. Renal abnormalities in a population of patients with psoriatic arthritis. Scand J Rheumatol 2001, 30:271-274. 10.1080/030097401753180345, 11727841.
21. Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, Orfanos CE. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol 1997, 77:305-308.
22. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250. 10.1097/01.ASN.0000108969.21691.5D, 14747370.
23. Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007, 34:332-335.
24. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
25. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, . EUVAS (European Vasculitis Study Group) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670-680. EUVAS (European Vasculitis Study Group).
26. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, . European Vasculitis Study Group Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188. 10.1681/ASN.2007010090, 17582159, European Vasculitis Study Group.
27. Medvedev G, Al-Shamari AE, Copland MA, Magil AB. Isolated renal giant cell arteritis. Am J Kidney Dis 2002, 40:658-661. 10.1053/ajkd.2002.34931, 12200821.
28. Bakkaloglu SA, Ekim M, Tumer N, Tulunay O, Ozer T. Severe renal impairment in the case of classic polyarteritis nodosa. Pediatr Nephrol 2001, 16:148-150. 10.1007/s004670000496, 11261683.
29. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008, 20:692-696. 10.1097/BOR.0b013e3283108df7, 18946330.
30. Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D. MPO-ANCA-positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease?. Am J Kidney Dis 1999, 33:e3.
31. Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med 1981, 141:643-645. 10.1001/archinte.141.5.643, 7224744.
32. Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. N Engl J Med 1986, 315:755-757. 10.1056/NEJM198609183151209, 3748084.
33. Rajakariar R, Sharples EJ, Raftery MJ, Sheaff M, Yaqoob MM. Sarcoid tubulointerstitial nephritis: long-term outcome and response to corticosteroid therapy. Kidney Int 2006, 70:165-169. 10.1038/sj.ki.5001512, 16688117.
34. Göbel U, Kettritz R, Schneider W, Luft F. The protean face of renal sarcoidosis. J Am Soc Nephrol 2001, 12:616-623.
35. Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney Int 2003, 63:716-721. 10.1046/j.1523-1755.2003.00771.x, 12631139.
36. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7:352-358. 10.1016/j.autrev.2008.02.001, 18486921.
37. Abu-Romeh SH, Johny KV. The erythrocyte sedimentation rate in end-stage renal disease [letter]. Am J Kidney Dis 1988, 12:169.
38. Liverman PC, Tucker FL, Bolton WK. Erythrocyte sedimentation rate in glomerular disease: association with urinary protein. Am J Nephrol 1988, 8:363-367. 10.1159/000167618, 3239598.
39. Kim RP. The musculoskeletal complications of diabetes. Curr Diab Rep 2002, 2:49-52. 10.1007/s11892-002-0057-7, 12643122.
40. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29:144-155. 10.1016/j.semnephrol.2009.01.007, 19371805.
41. Gaffo AL, Saag KG. Management of hyperuricemia and gout in CKD. Am J Kidney Dis 2008, 52:994-1009. 10.1053/j.ajkd.2008.07.035, 18971014.
42. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28. 10.1186/ar2143, 1906806, 17352828.
43. Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009, 76:424-426. 10.1016/j.jbspin.2009.01.001, 19289295.
44. De Angelis S, Noce A, Di Renzo L, Cianci R, Naticchia A, Giarrizzo GF, Giordano F, Tozzo C, Splendiani G, De Lorenzo A. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. Eur Rev Med Pharmacol Sci 2007, 11:179-184.
45. Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F. Recent progress in understanding dialysis-related amyloidosis. Bone 2009, 45(Suppl 1):S39-S42.
46. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663. 10.1001/archinte.164.6.659, 15037495.
47. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495. 10.1681/ASN.2004030203, 15590763.
48. National Kidney Foundation K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003, 41(4 Suppl 3):I-IV. S1-S91, National Kidney Foundation.
49. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 Suppl 1):S1-S290. National Kidney Foundation.
50. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12-S154. National Kidney Foundation.
51. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010, 362:56-65. 10.1056/NEJMcp0906797, 20054047.
52. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S. 10.1016/S0002-9343(99)00113-8, 10390124.
53. Hörl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals 2010, 3:2291-2321.
54. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992, 326:1654-1660. 10.1056/NEJM199206183262502, 1588978.
55. Panayi GS, Tugwell P. The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1997, 36:808-811. 10.1093/rheumatology/36.7.808, 9255119.
56. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999, 26:1176-1186.
57. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996, 39:272-276. 10.1002/art.1780390214, 8849378.
58. Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK. Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol 2009, 15:177-180. 10.1097/RHU.0b013e3181a61f2d, 19502905.
59. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM. Drug Prescribing in Renal Failure. Dosing Guidelines for Adults 1999, Philadelphia, PA: American College of Physicians-American Society of Internal Medicine, 4.
60. Swarup A, Sachdeva N, Schumacher HR. Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 2004, 10:190-204. 10.1097/01.rhu.0000135555.83088.a2, 17043508.
61. National Kidney Foundation KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530. National Kidney Foundation.
62. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
63. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2009, 53:617-627. 10.1053/j.ajkd.2008.08.033, 19027212.
64. Bardin T, Richette P. Nephrogenic systemic fibrosis. Curr Opin Rheumatol 2010, 22:54-58. 10.1097/BOR.0b013e328333bf3d, 19881349.